EF Hutton Reiterates Buy Rating on Enlivex Therapeutics (ENLV)

EF Hutton analyst Jason Kolbert reiterated a Buy rating and $13.00 price target on Enlivex Therapeutics (NASDAQ: ENLV).

The analyst commented, "Enlivex announced that the Danish Medicines Agency authorized the initiation of the Phase II stage of the company's multi-country Phase I/II trial in moderate and severe knee osteoarthritis. This approval follows the recently announced recommendation by the independent Data and Safety Monitoring board (DSMB) that the company may move forward to the Phase II stage of the trial. Why Denmark? It turns out that for what-ever reason Denmark has become a center of excellence where many of the world's OA studies begin. We see this as positive news for Enlivex."

For an analyst ratings summary and ratings history on Enlivex Therapeutics click here. For more ratings news on Enlivex Therapeutics click here.

Shares of Enlivex Therapeutics closed at $1.46 yesterday.

You May Also Be Interested In

• U.S. debt tops $40 trillion
• Silo Pharma acquires software assets from Parkview Consulting for stock
• Benchmark Starts SiTime Corp. (SITM) at Buy